Curetis N.V. Reports Results of the Extraordinary General Meeting Held on March 10, 2020

NEXT STORY
American Gene Technologies to Present at 2020 Inborn Errors of Metabolism Drug Development Summit in Boston
PREV STORY
VAXIL APPLIES FOR CORONAVIRUS VACCINE PATENT UNDER ITS ANTI-INFECTIVE VACCINES PLATFORM AND PROVIDES UPDATE ON THE EXERCISE OF WARRANTS
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Diamyd Medical starts producing proprietary GABA drug and expands its Scientific Advisory Board

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) today announced that production of a ...

author_avatar
NASDAQ Market News

Global $19.4 Bn Gene Expression Markets to 2028 – Rise in Investments for the Development of Alternative Drug Discovery Approaches

author_avatar
NASDAQ Market News

Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency

author_avatar
NASDAQ Market News